Drug Profile
Enapotamab vedotin - Genmab
Alternative Names: AXL-107-MMAE; HuMax-AXL; HuMax®-AXL-ADCLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Genmab
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 12 Nov 2021 Genmab completes a phase-I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Belgium, USA, Netherlands, Denmark and Spain(Parenteral) (NCT02988817)
- 24 Nov 2020 Discontinued - Phase-II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Belgium, USA, Netherlands, Denmark (Parenteral) as data from expansion cohorts did not meet stringent criteria for proof-of-concept